Oppenheimer Initiates Coverage On Larimar Therapeutics with Outperform Rating, Announces Price Target of $26

Benzinga · 10/16 09:09
Oppenheimer initiates coverage on Larimar Therapeutics (NASDAQ:LRMR) with a Outperform rating and announces Price Target of $26.